{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:41:15Z","timestamp":1792795275183,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","heartrhythmjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.hrthm.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:08:13Z","timestamp":1738973293000},"page":"1210-1217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of DOACs vs vitamin K antagonists in patients with atrial fibrillation and chronic kidney disease undergoing hemodialysis: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-4015","authenticated-orcid":false,"given":"El\u00edsio","family":"Bulh\u00f5es","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanio L.J.","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.R.","family":"Defante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mazetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Martins Rodrigues","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Ant\u00f4nio","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio Ibrahim","family":"Scanavacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Darrieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2025.02.009_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2010050459","article-title":"The increasing prevalence of atrial fibrillation among hemodialysis patients","volume":"22","author":"Winkelmayer","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hrthm.2025.02.009_bib2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/ki.2009.477","article-title":"Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy","volume":"77","author":"Wizemann","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.hrthm.2025.02.009_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2025.02.009_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348806","article-title":"Statin use and calcific uremic arteriolopathy: a matched case-control study","volume":"37","author":"Nigwekar","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.hrthm.2025.02.009_bib5","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/europace\/euq387","article-title":"Warfarin in haemodialysis patients with atrial fibrillation: what benefit?","volume":"12","author":"Yang","year":"2010","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2025.02.009_bib6","doi-asserted-by":"crossref","first-page":"F618","DOI":"10.1152\/ajprenal.00278.2020","article-title":"Vitamin K deficiency: an emerging player in the pathogenesis of vascular calcification and an iatrogenic consequence of therapies in advanced renal disease","volume":"319","author":"Levy","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.hrthm.2025.02.009_bib7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMra1505292","article-title":"Calciphylaxis","volume":"378","author":"Nigwekar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2025.02.009_bib8","series-title":"Non-Vitamin K Antagonist Oral Anticoagulants: A Concise Guide","author":"Shantsila","year":"2016"},{"key":"10.1016\/j.hrthm.2025.02.009_bib9","article-title":"Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis: a nationwide registry study","volume":"16","author":"Laville","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hrthm.2025.02.009_bib10","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study","volume":"16","author":"Lin","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.hrthm.2025.02.009_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1053\/j.ajkd.2022.03.007","article-title":"Apixaban dosing patterns versus warfarin in patients with nonvalvular atrial fibrillation receiving dialysis: a retrospective cohort study","volume":"80","author":"Wetmore","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hrthm.2025.02.009_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2023.08.020","article-title":"Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: a systematic review and meta-analysis","volume":"119","author":"Kyriakoulis","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.hrthm.2025.02.009_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000713","article-title":"Direct oral anticoagulants exhibit lower risks of mortality and bleeding compared to vitamin K antagonists in atrial fibrillation patients on chronic hemodialysis: a systematic review and meta-analysis [E-pub ahead of print]","author":"Goyal","year":"2024","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.hrthm.2025.02.009_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11239-023-02945-0","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: a systematic review and meta-analysis of randomized controlled trials","volume":"57","author":"de Lucena","year":"2024","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.hrthm.2025.02.009_bib15","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s11255-023-03889-3","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation on chronic hemodialysis: a meta-analysis of randomized controlled trials","volume":"56","author":"Navalha","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.hrthm.2025.02.009_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.hrthm.2025.02.009_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.hrthm.2025.02.009_bib18","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hrthm.2025.02.009_bib19","article-title":"RoB 2: a revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.hrthm.2025.02.009_bib20","first-page":"1","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","author":"McGuinness","year":"2020","journal-title":"Res Syn Meth"},{"key":"10.1016\/j.hrthm.2025.02.009_bib21","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hrthm.2025.02.009_bib22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.02.009_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.02.009_bib24","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.0000000000000495","article-title":"Anticoagulation for patients with atrial fibrillation receiving dialysis: a pilot randomized controlled trial [E-pub ahead of print]","author":"Harel","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.hrthm.2025.02.009_bib25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2025.02.009_bib26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2025.02.009_bib27","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2025.02.009_bib28","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2025.02.009_bib29","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2025.02.009_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125001249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527125001249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T08:38:30Z","timestamp":1745915910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527125001249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1547527125001249"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.02.009","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of DOACs vs vitamin K antagonists in patients with atrial fibrillation and chronic kidney disease undergoing hemodialysis: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}